510 related articles for article (PubMed ID: 16461435)
21. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
[TBL] [Abstract][Full Text] [Related]
22. Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF alpha antagonists.
Feito JG; Pereda CA
J Clin Rheumatol; 2009 Oct; 15(7):363-5. PubMed ID: 20009975
[TBL] [Abstract][Full Text] [Related]
23. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
Gisondi P; Cotena C; Tessari G; Girolomoni G
J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):341-4. PubMed ID: 18005022
[TBL] [Abstract][Full Text] [Related]
24. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
[TBL] [Abstract][Full Text] [Related]
25. Etanercept and infliximab for rheumatoid arthritis.
Drug Ther Bull; 2001 Jul; 39(7):49-52. PubMed ID: 11471515
[TBL] [Abstract][Full Text] [Related]
26. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy.
Tse SM; Burgos-Vargas R; Laxer RM
Arthritis Rheum; 2005 Jul; 52(7):2103-8. PubMed ID: 15986366
[TBL] [Abstract][Full Text] [Related]
27. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease.
Smith JR; Levinson RD; Holland GN; Jabs DA; Robinson MR; Whitcup SM; Rosenbaum JT
Arthritis Rheum; 2001 Jun; 45(3):252-7. PubMed ID: 11409666
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study.
Guignard S; Gossec L; Salliot C; Ruyssen-Witrand A; Luc M; Duclos M; Dougados M
Ann Rheum Dis; 2006 Dec; 65(12):1631-4. PubMed ID: 16901960
[TBL] [Abstract][Full Text] [Related]
29. Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis.
De Filippis L; Caliri A; Anghelone S; Scibilia G; Lo Gullo R; Bagnato G
Panminerva Med; 2006 Jun; 48(2):129-35. PubMed ID: 16953150
[TBL] [Abstract][Full Text] [Related]
30. Anti-TNF-alpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital.
Petropoulos IK; Vaudaux JD; Guex-Crosier Y
Klin Monbl Augenheilkd; 2008 May; 225(5):457-61. PubMed ID: 18454398
[TBL] [Abstract][Full Text] [Related]
31. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
32. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases.
Fautrel B; Sibilia J; Mariette X; Combe B;
Ann Rheum Dis; 2005 Feb; 64(2):262-6. PubMed ID: 15184196
[TBL] [Abstract][Full Text] [Related]
33. Etanercept therapy in children with treatment-resistant uveitis.
Reiff A; Takei S; Sadeghi S; Stout A; Shaham B; Bernstein B; Gallagher K; Stout T
Arthritis Rheum; 2001 Jun; 44(6):1411-5. PubMed ID: 11407702
[TBL] [Abstract][Full Text] [Related]
34. [Anti-TNF-α in the treatment of uveitis in the Besançon Hospital].
Fery-Blanco C; Schwartz C; Gil H; Curlier E; Prati C; Delbosc B
J Fr Ophtalmol; 2011 Dec; 34(10):697-702. PubMed ID: 21889230
[TBL] [Abstract][Full Text] [Related]
35. The significance of persistent newly developed autoantibodies in JIA patients under long-term anti-TNF treatment.
Kanakoudi-Tsakalidou F; Tzimouli V; Pratsidou-Gertsi P; Chronopoulou E; Trachana M
Cytokine; 2008 Jun; 42(3):293-7. PubMed ID: 18445529
[TBL] [Abstract][Full Text] [Related]
36. Retrospective case review of pediatric patients with uveitis treated with infliximab.
Rajaraman RT; Kimura Y; Li S; Haines K; Chu DS
Ophthalmology; 2006 Feb; 113(2):308-14. PubMed ID: 16406545
[TBL] [Abstract][Full Text] [Related]
37. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P
Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231
[TBL] [Abstract][Full Text] [Related]
38. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.
Kapetanovic MC; Saxne T; Nilsson JA; Geborek P
Rheumatology (Oxford); 2007 Apr; 46(4):608-11. PubMed ID: 17114801
[TBL] [Abstract][Full Text] [Related]
39. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation.
Theodossiadis PG; Markomichelakis NN; Sfikakis PP
Retina; 2007; 27(4):399-413. PubMed ID: 17420690
[TBL] [Abstract][Full Text] [Related]
40. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.
Mohan N; Edwards ET; Cupps TR; Slifman N; Lee JH; Siegel JN; Braun MM
J Rheumatol; 2004 Oct; 31(10):1955-8. PubMed ID: 15468359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
